#USA #New York #Hoth Therapeutics #GDNF #HT-VA Study

Hoth Therapeutics Announces Groundbreaking HT-VA Study Results

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a prominent clinical-stage biopharmaceutical company, has released impressive new findings from its HT-VA study. This research, conducted in collaboration with the U.S. Department of Veterans Affairs and Emory University, demonstrates that glial cell-derived neurotrophic factor (GDNF) can directly modify liver fat metabolism on a genetic level. The implications of this breakthrough are vast, particularly for conditions like metabolic-associated fatty liver disease (MAFLD) and obesity.

Key Findings of the HT-VA Study

Hoth's data indicates several statistically significant developments for GDNF in its approach to treating MAFLD and obesity:

• - A noteworthy reduction of Srebf1, a gene pivotal in fat production in the liver, suggests that GDNF can effectively minimize the creation of fatty acids.
• - An increase in Pparα, a central player in fat metabolism and burning, points to GDNF's ability to enhance the body’s capability to utilize stored fats.
• - Remarkably, GDNF has outperformed conventional treatments like semaglutide in terms of expressing these key genetic markers linked to liver fat regulation.

This dual-action mechanism highlights GDNF's unique position in therapeutic approaches, focusing not just on weight loss but on directly addressing the root biological processes that lead to fat accumulation in the liver.

GDNF: A New Hope for Patients

Current therapies primarily concentrate on reducing body weight, but they often fail to tackle the underlying causes of metabolic dysfunctions. GDNF is distinct as it actively intervenes at the genetic level, offering a paradigm shift in treating liver health and broader metabolic concerns. The core benefits outlined include:

• - Srebf1 reduction results in less fat being synthesized.
• - Pparα activation leads to an increase in the burning of stored fat.
• - The overall outcome is a comprehensive reprogramming of liver metabolism, which holds promise for treating obesity, MAFLD, and other metabolic disorders effectively.

In light of these findings, Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm about the future applications of GDNF therapy. He stated, "These results demonstrate that GDNF is not just reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. This positions GDNF as a novel therapy distinct from GLP-1 agonists."

Detailed Scientific Observations

The HT-VA study utilized a model of diet-induced obesity combined with MAFLD to assess the efficacy of GDNF. Key observations from this research included:

• - Those on a Western diet displayed substantial liver fat accumulation and notable metabolic dysfunctions.
• - Treatment with GDNF resulted in significant enhancements in liver gene expressions associated with fat metabolism.
• - There was a marked decrease in lipogenesis signaling, specifically via reduced Srebf1 activity, alongside boosted metabolic regulation pathways involving Pparα.

These genetic expression adjustments support improved lipid handling by the liver, enhancing overall metabolic efficiency.

Strategic Future Directions

Hoth Therapeutics is looking to build upon the promising findings of the HT-VA study. Plans moving forward include:

• - Initiating further preclinical validation studies based on HT-VA findings.
• - Evaluating potential pathways for clinical development focusing on metabolic and hepatic diseases.
• - Exploring strategic partnerships to expedite the development of this groundbreaking therapy.

As a clinical-stage biopharmaceutical company, Hoth Therapeutics remains committed to developing innovative treatments that meaningfully enhance patients' lives. The company prioritizes collaboration with a diverse team of scientists and clinicians to explore new therapeutic avenues, further establishing its role as a leader in pharmaceutical research and development.

For more information on Hoth Therapeutics and its advancements, please visit Hoth Therapeutics Investor Relations.